66 completed, 4 terminated, 1 active not recruiting, 1 no longer available. 25 Phase 3, 23 Phase 1, 11 Phase 2, 3 Phase 4, 1 Not applicable.
By phase and status
Follow Janssen-Cilag International NV: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq. - Schizophrenia | Phase 4 | Completed | Janssen-Cilag International NV | 93 | 2021-07-22 | 2025-04-27 |
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Major | Phase 3 | Completed | Janssen-Cilag International NV | 676 | 2020-08-21 | 2025-04-29 |
TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study
Global/single cell gene expression profiles obtained from Synovial biopsies - Psoriatic Arthritis | Not applicable | Completed | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 36 | 2020-01-14 | 2023-09-18 |
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Treatment-Resistant | Phase 3 | Withdrawn | Janssen-Cilag International NV | | 2019-12-01 | 2025-04-27 |
A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment
Pimodivir - Kidney Failure, Chronic | Phase 1 | Terminated | Janssen-Cilag International NV | 29 | 2019-07-02 | 2025-02-03 |
A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment
Pimodivir - Hepatic Impairment | Phase 1 | Completed | Janssen-Cilag International NV | 42 | 2019-05-28 | 2025-02-03 |
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
Guselkumab, Placebo Injection - Psoriasis | Phase 3 | Completed | Janssen-Cilag International NV | 880 | 2019-02-08 | 2026-01-23 |
A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults
Pimodivir, Cyclosporine - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 18 | 2018-12-06 | 2019-04-29 |
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
Paliperidone Palmitate 3-Month Formulation (PP3M) - Schizophrenia | | Completed | Janssen-Cilag International NV | 225 | 2018-11-21 | 2025-04-27 |
A Study to Determine the Epidemiology and Evaluate the Burden of Disease in Respiratory Syncytial Virus/Human Metapneumovirus and Influenza A Infected Hospitalized Participants (Adults and Children)
Respiratory Tract Infections | | Completed | Janssen-Cilag International NV | 118 | 2018-06-27 | 2021-02-02 |
A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol
JNJ-55308942 High Dose, JNJ-55308942 Low Dose, Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC) - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 14 | 2018-06-08 | 2025-04-27 |
A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739
JNJ-55308942, [18F]-JNJ-64413739 - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 13 | 2018-03-15 | 2025-04-27 |
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
Ustekinumab - Psoriasis | | Active not recruiting | Janssen-Cilag International NV | 135 | 2017-10-25 | 2026-09-25 |
A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants
Ethinyl Estradiol + Levonorgestrel, JNJ-42847922 - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 24 | 2017-08-14 | 2025-04-27 |
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants
JNJ-55308942 0.5 mg, JNJ-55308942 1.5 mg, JNJ-55308942 4 mg - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 98 | 2017-05-03 | 2025-04-27 |
A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults
JNJ-64041575, Probenecid - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 18 | 2017-04-05 | 2018-08-13 |
A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739
JNJ-54175446, 18F-JNJ-64413739 - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 16 | 2017-03-24 | 2025-04-27 |
A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants
JNJ-63623872, Oseltamivir - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 45 | 2017-02-14 | 2017-05-25 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274
JNJ-48816274, Placebo - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 90 | 2016-08-13 | 2025-04-27 |
Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults
JNJ-63623872, Placebo - Healthy | Phase 1 | Completed | Janssen-Cilag International NV | 66 | 2016-08-08 | 2018-01-30 |
Showing 20 of 74. Sign in to see all of them.
Conditions studied
Schizophrenia (12) · Multiple Myeloma (7) · Hepatitis C (6) · Hepatitis C, Chronic (5) · Acquired Immunodeficiency Syndrome (3) · Agnosia (3) · Infections (3) · Psoriasis (3) · Recurrence (3) · Attention Deficit Disorder with Hyperactivity (2) · Bone Marrow Neoplasms (2) · Depressive Disorder, Major (2) · HIV Infections (2) · Kidney Failure, Chronic (2) · Pain (2)
Interventions
Bortezomib (9) · Paliperidone Palmitate (8) · Ribavirin (5) · pimodivir (5) · telaprevir (5) · peginterferon alfa-2a (4) · seltorexant (4) · Dexamethasone (3) · JNJ-55308942 (3) · Simeprevir (3) · (18)F-JNJ-64413739 (2) · Antipsychotic Agents (2) · Canagliflozin (2) · Cyclophosphamide (2) · Darunavir (2)
Countries
Germany (39) · Belgium (36) · France (26) · Spain (24) · United Kingdom (23) · Austria (16) · Greece (16) · Denmark (15) · Hungary (15) · Russia (15) · Netherlands (13) · Sweden (13) · Israel (12) · Poland (12) · Portugal (11)
Top investigators
Bertrand Coiffier, MD (2) · Alain Delmer, MD (1) · Elisabetta Munzone, MD (1) · Vincent Ribrag, MD (1) · Wolfgang Knauf, MD (1)
Results publications
PMID 17519263, PMID 19371392, PMID 19959339, PMID 20010070, PMID 21150563, PMID 21696265, PMID 21798108, PMID 21881478, PMID 22210755, PMID 24491033, PMID 24597755, PMID 25261096, PMID 25444566, PMID 26293513, PMID 26398503, PMID 26416471, PMID 26483516, PMID 27279571, PMID 27428331, PMID 27790789, PMID 28056030, PMID 28135777, PMID 28640988, PMID 28801967, PMID 28851109, PMID 29924507, PMID 31181017, PMID 32155662, PMID 32606705, PMID 32840872, PMID 34518264, PMID 35201607, PMID 35774109, PMID 37756123, PMID 37792613, PMID 38169502, PMID 38169503, PMID 38954874, PMID 39083288, PMID 42298878, PMID 42303401
NIH funding
2016 (6), 2018 (6), 2015 (5), 2008 (3), 2014 (3), 2017 (3), 2004 (1), 2005 (1), 2019 (1), 2023 (1)